← Leaderboards
Jay Cooper
New York University School Of Medicine
$168,048
Attributed
$168,048
Total exposure
8
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$168,048 · 8
By mechanism
M01$168,048 · 8
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Kam-Meng Tchou-Wong$3,861,790
- Alvin E Friedman-Kien$98,126
- Kenichi Takeshita$106,090
- Fritz Francois$916,188
Others in their field
Top investigators on “Neoplasm /Cancer Radiation Therapy”
- Charles A Coltman · Southwest Oncology Group$65,101,418
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$47,533,330
- Walter J Curran · Thomas Jefferson University$41,640,321
- Samuel A Wells · Duke University$32,148,803
- John H. Glick · University Of Pennsylvania$26,662,963
Research focus
Neoplasm /Cancer Radiation TherapyHuman SubjectClinical ResearchHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyCombination Cancer TherapyNeoplasm /Cancer SurgeryHead /Neck NeoplasmFluorouracilCis Platinum Compound5 FluorouridineClinical TrialsCombination TherapyDrug Adverse EffectLeucovorinSquamous Cell CarcinomaGliomaFemaleEsophagus NeoplasmCombination ChemotherapyHydroxyureaLarynxVulva NeoplasmsLevamisole
Grant awards (32)
POST-OP CHEMOTHERAPY AS SHORT VERSUS PROLONGED INFUSION + RT FOR RECTAL CANCER$0
M01 · FY2002 · RR
ADJUVANT CHEMORADIATION AFTER GASTRIC RESECTION FOR ADENOCARCINOMA$0
M01 · FY2002 · RR
CONCURRENT RT PLUS CHEMOTHERAPY FOR ADVANCED SSCA OF THE HEAD AND NECK$0
M01 · FY2002 · RR
SURGERY FOLLOWED BY RT VERSUS RADIOCHEMOTHERAPY IN RESECTABLE HEAD/NECK CA$0
M01 · FY2002 · RR
RTOG 9612 CHEMORADIATION IN LOCALLY EXTENSIVE EPIDERMOID CA OF THE VULVA$0
M01 · FY2002 · RR
RTOG94-05 HIGH DOSE VERSUS CONVENTIONAL RT FOR CARCINOMA OF ESOPHAGUS$0
M01 · FY2002 · RR
RTOG 91-1--OPTIMAL REGIMEN (CHEMOTHERAPY AND RT) TO PRESERVE THE LARYNX$0
M01 · FY2002 · RR
RADIATION ALONE VS PRERADIATION CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIOMAS$0
M01 · FY2002 · RR
POST-OP CHEMOTHERAPY AS SHORT VERSUS PROLONGED INFUSION + RT FOR RECTAL CANCER$0
M01 · FY2001 · RR
RADIATION ALONE VS PRERADIATION CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIOMAS$0
M01 · FY2001 · RR
RTOG 91-1--OPTIMAL REGIMEN (CHEMOTHERAPY AND RT) TO PRESERVE THE LARYNX$0
M01 · FY2001 · RR
RTOG94-05 HIGH DOSE VERSUS CONVENTIONAL RT FOR CARCINOMA OF ESOPHAGUS$0
M01 · FY2001 · RR
RTOG 9612 CHEMORADIATION IN LOCALLY EXTENSIVE EPIDERMOID CA OF THE VULVA$0
M01 · FY2001 · RR
SURGERY FOLLOWED BY RT VERSUS RADIOCHEMOTHERAPY IN RESECTABLE HEAD/NECK CA$0
M01 · FY2001 · RR
CONCURRENT RT PLUS CHEMOTHERAPY FOR ADVANCED SSCA OF THE HEAD AND NECK$0
M01 · FY2001 · RR
ADJUVANT CHEMORADIATION AFTER GASTRIC RESECTION FOR ADENOCARCINOMA$0
M01 · FY2001 · RR
ADJUVANT CHEMORADIATION AFTER GASTRIC RESECTION FOR ADENOCARCINOMA$21,006
M01 · FY2000 · RR
RTOG94-05 HIGH DOSE VERSUS CONVENTIONAL RT FOR CARCINOMA OF ESOPHAGUS$21,006
M01 · FY2000 · RR
RTOG 91-1--OPTIMAL REGIMEN (CHEMOTHERAPY AND RT) TO PRESERVE THE LARYNX$21,006
M01 · FY2000 · RR
RADIATION ALONE VS PRERADIATION CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIOMAS$21,006
M01 · FY2000 · RR
POST-OP CHEMOTHERAPY AS SHORT VERSUS PROLONGED INFUSION + RT FOR RECTAL CANCER$21,006
M01 · FY2000 · RR
RTOG 9612 CHEMORADIATION IN LOCALLY EXTENSIVE EPIDERMOID CA OF THE VULVA$21,006
M01 · FY2000 · RR
SURGERY FOLLOWED BY RT VERSUS RADIOCHEMOTHERAPY IN RESECTABLE HEAD/NECK CA$21,006
M01 · FY2000 · RR
CONCURRENT RT PLUS CHEMOTHERAPY FOR ADVANCED SSCA OF THE HEAD AND NECK$21,006
M01 · FY2000 · RR
POST-OP CHEMOTHERAPY AS SHORT VERSUS PROLONGED INFUSION + RT FOR RECTAL CANCER$0
M01 · FY2000 · RR
RTOG94-05 HIGH DOSE VERSUS CONVENTIONAL RT FOR CARCINOMA OF ESOPHAGUS$0
M01 · FY2000 · RR
RTOG 9612 CHEMORADIATION IN LOCALLY EXTENSIVE EPIDERMOID CA OF THE VULVA$0
M01 · FY2000 · RR
RTOG 91-1--OPTIMAL REGIMEN (CHEMOTHERAPY AND RT) TO PRESERVE THE LARYNX$0
M01 · FY2000 · RR
ADJUVANT CHEMORADIATION AFTER GASTRIC RESECTION FOR ADENOCARCINOMA$0
M01 · FY2000 · RR
RADIATION ALONE VS PRERADIATION CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIOMAS$0
M01 · FY2000 · RR
SURGERY FOLLOWED BY RT VERSUS RADIOCHEMOTHERAPY IN RESECTABLE HEAD/NECK CA$0
M01 · FY2000 · RR
CONCURRENT RT PLUS CHEMOTHERAPY FOR ADVANCED SSCA OF THE HEAD AND NECK$0
M01 · FY2000 · RR